Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODUL: Biomarker-Driven Maintenance Treatment for First-Line Metastatic Colorectal Cancer
2014-001017-61Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab in metastatic colorectal adenocarcinoma (mCRC), sponsored by Roche. Primary endpoint: Early tumor size reduction at 2 months. Started Sep 2014; status: completed.
02
Drugs
bevacizumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2014-001017-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001017-61.